266
Views
6
CrossRef citations to date
0
Altmetric
Research Articles

Impact of combined oral contraceptives containing ethinylestradiol on the liver microsomal metabolism

, , , , &
Pages 284-292 | Published online: 06 May 2013

REFERENCES

  • Afolabi P, Wright M, Wootton SA, Jackson AA. Clinical utility of 13C-liver-function breath tests for assessment of hepatic function. Dig Dis Sci 2013;58:33–41.
  • Kasicka-Jonderko A, Jonderko K. Phase-1 evaluation of 13C-liver function breath tests. Dig Dis Sci 2013;58: 579–81.
  • Kasicka-Jonderko A, Nita A, Jonderko K, et al. 13C-methacetin breath test reproducibility study reveals persistent CYP1A2 stimulation on repeat examinations. World J Gastroenterol 2011;17:4979–86.
  • Ciccocioppo R, Candelli M, Di Francesco D, et al. Study of liver function in healthy elderly subjects using the 13C-methacetin breath test. Aliment Pharmacol Ther 2003;17:271–7.
  • Kasicka-Jonderko A, Jonderko K, Chabior E, et al. Exact profiles of 13CO2 recovery in breath air after per oral administration of 13C-methacetin in two groups of different age. Isotopes Environ Health Stud 2008;44: 295–303.
  • Zipprich A, Meiss F, Steudel N, et al. 13C-Methacetin metabolism in patients with cirrhosis: Relation to disease severity, haemoglobin content and oxygen supply. Aliment Pharmacol Ther 2003;17:1559–62.
  • Wutzke KD, Forberger A, Wigger M. Effect of alcohol consumption on the liver detoxication capacity as measured by [13C]methacetin- and [methyl-13C]methionine-breath tests. Isotopes Environ Health Stud 2008;44: 219–26.
  • Kasicka-Jonderko A, Loska D, Jonderko K, et al. Interference of acute cigarette smoking with [13C]methacetin breath test. Isotopes Environ Health Stud 2011;47:34–41.
  • Opekun AR, Jr., Klein PD, Graham DY. [13C]Aminopyrine breath test detects altered liver metabolism caused by low-dose oral contraceptives. Dig Dis Sci 1995;40:2417–22.
  • Van Vlierberghe H, Van Durme F, Verdievel H, et al. Influence of low-dose oral contraceptives, alcohol, and grapefruit on [13C]aminopyrine breath test. Dig Dis Sci 2001;46:133–9.
  • Preamble to the Constitution of the World Health Organization as adopted by the International Health Conference, New York, 19 June–22 July 1946; signed on 22 July 1946 by the representatives of 61 States (Official Records of the World Health Organization, no. 2, p. 100) and entered into force on 7 April 1948. Accessed 6 March 2013 from: http://www.who.int/about/definition/en/print.html
  • Armitage P. Statistical methods in medical research. Oxford: Blackwell Scientific Publications 1978.
  • StatSoft, Inc. Electronic statistics textbook. Tulsa, OK: StatSoft 2012. Accessed 6 March 2013 from: http://www.statsoft.com/textbook/
  • Purba HS, Maggs JL, Orme ML, et al. The metabolism of 17 alpha-ethinyloestradiol by human liver microsomes: Formation of catechol and chemically reactive metabolites. Br J Clin Pharmacol 1987;23:447–53.
  • Maggs JL, Grabowski PS, Park BK. Drug protein conjugates–III. Inhibition of the irreversible binding of ethinylestradiol to rat liver microsomal protein by mixed-function oxidase inhibitors, ascorbic acid and thiols. J Steroid Biochem 1983;19:1273–8.
  • Guengerich FP, Martin MV, Beaune PH, et al. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1986;261:5051–60.
  • Omura T, Saito R. The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. J Biol Chem 1964;239: 2370–8.
  • Wang B, Sanchez RI, Franklin RB, et al. The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos 2004;32: 1209–12.
  • Guengerich FP. Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol 1988;33:500–8.
  • Kent UM, Lin HL, Mills DE, et al. Identification of 17-alpha-ethynylestradiol-modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6. Chem Res Toxicol 2006;19:279–87.
  • Kapp N, Tilley IB, Curtis KM. The effects of hormonal contraceptive use among women with viral hepatitis or cirrhosis of the liver: A systematic review. Contraception 2009;80:381–6.
  • Sitruk-Ware R, Nath A. Metabolic effects of contraceptive steroids. Rev Endocr Metab Disord 2011;12:63–75.
  • Chabbert-Buffet N, Chassard D, Ochsenbein E, et al. Inhibition of ovulation by NOMAC/E2, a novel monophasic oral contraceptive combining nomegestrol acetate and 17β-oestradiol: A double-blind, randomised, dose-finding pilot study. Eur J Contracept Reprod Health Care 2011;16:76–84.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.